HRS-9821 inhalation treatment for moderate to severe COPD
Part of Lungs & breathing clinical trials.
This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–79 years old
- Diagnosed with COPD for at least 1 year, with stable treatment for 4 weeks before starting
- Smoking history of at least 10 pack-years (roughly 1 pack daily for 10 years, or equivalent)
- Lung function tests show FEV1 between 30% and 80% of normal, and FEV1/FVC ratio below 0.7
- Moderate or worse shortness of breath (mMRC score 2 or higher)
- No serious heart disease, recent COPD flare-ups, major infections, or other lung conditions that would interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.
This trial tests an inhaled medication for COPD. It aims to see if the treatment is safe and helps improve breathing and symptoms.
This study tests a new inhaled medication called HSK39004 for people with COPD. The goal is to see if it is safe and effective over the long term, and to compare it with a placebo to find out how well it helps with breathing.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
This study tests an inhaled medication that may help improve breathing and reduce flare-ups in people with moderate-to-severe COPD. If you qualify, you'll use the study drug through a nebulizer at home and have regular check-ups to see how it works.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.